The Protease ADAM17 at the Crossroads of Disease: Revisiting its Significance in Inflammation, Cancer, and Beyond.
Mohamed I SaadBrendan J JenkinsPublished in: The FEBS journal (2023)
The protease A Disintegrin And Metalloproteinase 17 (ADAM17) plays a central role in the pathophysiology of several diseases. ADAM17 is involved in the cleavage and shedding of at least 80 known membrane-tethered proteins, which subsequently modulate several intracellular signaling pathways, and therefore alter cell behavior. Dysregulated expression and/or activation of ADAM17 has been linked to a wide range of autoimmune and inflammatory diseases, cancer and cardiovascular disease. In this review, we provide an overview of the current state of knowledge from preclinical models and clinical data on the diverse pathophysiological roles of ADAM17, and discuss the mechanisms underlying ADAM17-mediated protein shedding and the potential therapeutic implications of targeting ADAM17 in these diseases.
Keyphrases
- cardiovascular disease
- papillary thyroid
- oxidative stress
- healthcare
- signaling pathway
- poor prognosis
- stem cells
- squamous cell
- machine learning
- single cell
- electronic health record
- metabolic syndrome
- mesenchymal stem cells
- bone marrow
- drug delivery
- transcription factor
- lymph node metastasis
- cardiovascular events
- drug induced